A Review of Sitaxsentan Sodium in Patients with Pulmonary Arterial Hypertension
DSpace/Manakin Repository
A Review of Sitaxsentan Sodium in Patients with Pulmonary Arterial Hypertension
| Title: | A Review of Sitaxsentan Sodium in Patients with Pulmonary Arterial Hypertension |
| Author: | Waxman, Aaron Bradley |
| Citation: | Waxman, Aaron B. 2007. A review of sitaxsentan sodium in patients with pulmonary arterial hypertension. Vascular Health and Risk Management 3(1): 151-157. |
| Full Text & Related Files: |
1994033.pdf (76.09Kb; PDF) 
|
| Abstract: | Pulmonary arterial hypertension (PAH) is a life threatening, progressive condition which eventually leads to fatal right heart failure. Endothelin-1 (ET-1), a potent vasoconstrictor peptide, is increased in the pulmonary arteries of patients with pulmonary hypertension. Endothelin-1 acts through the stimulation of 2 subtypes of receptors (endothelin receptor subtypes A [ET\(_A\)] and B [ET\(_B\)]). In PAH patients, ETRAs block the deleterious vasoconstrictor effects of ET-1, and ETRA treatment in PAH patients has been shown to be safe and efficacious. Sitaxsentan is an orally active, highly ET\(_A\) selective ETRA that, in clinical trials, has demonstrated improvements in exercise capacity, functional class and hemodynamics in PAH patients. Sitaxsentan has been shown to be safe, well tolerated, and associated with a lower incidence of liver toxicity than other approved ETRAs. |
| Other Sources: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994033/pdf/ |
| Terms of Use: | This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
| Citable link to this page: | http://nrs.harvard.edu/urn-3:HUL.InstRepos:10246869 |
| Downloads of this work: |
This item appears in the following Collection(s)
-
HMS Scholarly Articles [20474]
Contact administrator regarding this item (to report mistakes or request changes)
